Companies in the News

Millendo Therapeutics acquires French biopharmaceutical company

Millendo Therapeutics acquires Alize Pharma in stock-based transaction Merger beefs up Millendo's congenital adrenal hyperplasia program Alize Pharma is known for developing treatment for Prader-Willi syndrome Millendo Therapeutics Inc. has acquired Alizé Pharma SAS in a stock-based transaction, the Ann Arbor-based biopharmaceutical company announced Wednesday. The deal includes Alizé Pharma's facilities, operations and staff, which will handle research and development. Alize is a French biopharmaceutical company that creates treatments for metabolic and rare diseases. The drugmaker is known for livoletide, formerly known as AZP-531, for treating Prader-Willi syndrome, a genetic condition th

Grain Craft & Indigo Announce Consumer-Driven Supply Agreement for One Million Bushels of Identi

• Indigo to provide Grain Craft with wheat that is sustainably produced, identity preserved, and meets enhanced milling quality standards Boston, Massachusetts, December 12, 2017 – Grain Craft, the largest independent flour milling company in the United States, has partnered with Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, in a supply agreement for one million bushels of high quality, sustainably produced, and identity preserved wheat. Indigo has already partnered with hundreds of U.S. farmers to produce Indigo WheatTM at a premium of 43 cents per bushel over the price of commodity wheat. When the crop is harvested in 2018, Indigo

Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-

Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59th Annual Meeting and Exposition SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that data presented in a poster session at the American Society of Hematology (ASH) 59th Meeting and Annual Exhibition demonstrate clinical activity, including one partial response, for the company’s lead product candidate, eFT508. In addition, preclinical data presented for another candidate, eFT226, demonstrated the potential for that compound in B-cell malignancies. Data

Farming startup Indigo raises $203 million with help from Dubai fund

SAN FRANCISCO (Reuters) - Farming technology startup Indigo has raised more than $200 million from investors to fund its efforts to reform how crops including wheat, soybeans, cotton and corn are grown around the world. The Boston-based company announced on Wednesday an additional $47 million investment led by the Investment Corporation of Dubai, a state-owned sovereign wealth fund, bringing its latest financing round to $203 million. Indigo is valued after the latest round at $1.4 billion, Indigo’s President and Chief Executive David Perry said in an interview. The financing is one of the largest single investments into a private agriculture-technology company. It rivals SoftBank Group Corp